Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Director's Dealing 2020

May 7, 2020

29777_dirs_2020-05-07_b0f7e438-bd10-4880-9de8-607085636a16.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2020-05-05

Reporting Person: LANE ANDREW H (Executive Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-05-05 Common shares without par value M 41268 $48.90 Acquired 107090 Direct
2020-05-05 Common shares without par value M 38732 $38.40 Acquired 145822 Direct
2020-05-05 Common shares without par value S 80000 $92.0013 Disposed 65822 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-05-05 Option (right to buy) $48.90 M 41268 Disposed 2025-05-31 Common shares (41268) Direct
2020-05-05 Option (right to buy) $38.40 M 38732 Disposed 2026-02-18 Common shares (38732) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common shares without par value 1428 Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.02, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of May 5, 2020.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.